News Posts List
Boulder Backroads 1/2 Marathon
09/30/2007
Steve Clark Memorial Benefit
09/29/2007
immatics launches Phase 2 study on cancer vaccine IMA901
09/27/2007
Today immatics biotechnologies announced the start of a Europe-wide Phase 2 clinical study on its IMA901 product candidate, a peptide-based therapeutic vaccine for the treatment of renal cell cancer. With this move, the Tuebingen-based biotechnology company is swiftly building upon its Phase 1 study, which was successfully concluded in 2006 and whose highly promising results were presented at this years Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. In addition to safety and tolerability, the Phase 1 study also demonstrated IMA901s immunological efficacy, as well as a correlation between the immune response that it stimulates and a stabilization of the disease in renal cancer cell patients.
A new drug has shown promise in patients with advanced kidney cancer.
09/26/2007
Barcelona, Spain: A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumor fails to respond to therapy.
5th Annual Uncle Omer Open Golf Tournament
09/22/2007
New Report Provides Insight into the Pipeline Status of Kidney Cancer Drugs by Company and by Stage
09/19/2007
Research and Markets (http://www.researchandmarkets.com/reports/c68874) has announced the addition of "Kidney Cancer Drug Pipeline Report" to their offering. "Kidney Cancer Drug Pipeline Report" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of kidney cancer drugs by company and by stage as well as a summary of the latest news and developments in this area. Source: Business Wire
Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
09/14/2007
Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has submitted a comprehensive data report elating to XL880 to GlaxoSmithKline (GSK). As announced in August 2007, GSK requested to initiate its review of XL880 before the compound reaches proof-of-concept as defined under the product development and commercialization agreement between the two companies. GSK now has 90 days to review the data package and determine if it will select the compound for further clinical development and commercialization Source: Exelixis, Inc.
Betting on Nanotech Therapies
09/12/2007
Some venture capitalists are betting that tiny instruments will drive big advances in cancer care. Several investors are funding start-ups that use nanotechnology -- the manipulation of matter on the scale of the nanometer, a billionth of a meter -- to create therapies that destroy tumors and spare healthy cells. Source: The Wall Street Journal
Biking for a Cure in Boston
09/09/2007
News Feed